Legal and Regulatory Instruments to Address Collusive Practices in Healthcare Delivery

17 Pages Posted: 12 Jul 2010 Last revised: 14 Jul 2010

See all articles by Yogesh Pai

Yogesh Pai

National Law University Delhi, Centre for Innovation, IP and Competition (CIIPC)

Date Written: July 6, 2010

Abstract

The Competition Act, 2002 (as amended up to date) was enacted with an object, keeping in view economic development of the country, to ensure that anticompetitive practices do not occur within different markets and to ensure that consumers get the benefits of the new market economy. It replaced the archaic MRTP Act, which excessively relied on structure, conduct and performance. The new Competition Act was enacted to bring about substantial changes in ways that anticompetitive agreements, monopolies and combinations in several sectors are treated.

One among various sectors prone to rampant anticompetitive practices is the healthcare sector. The healthcare sector is one of the most sensitive of all since it is marred by greater degree of information asymmetries when compared to other sectors. It is critically so in case of pharmaceutical drugs and therapeutics where the doctor chooses and the consumer pays - more so in the case of "ethical drugs" or prescription drug markets. One unique situation in pharmaceuticals is that the costliest brand is also the highest preferred brand. This has led to a host of practices being followed right from how drugs reach the supply chain and how doctors tend to prescribe a particular brand. Unfortunately, laws dealing with supply chain practices are quite lax. The problem is also with lack of adequate enforcement of ex-ante regulatory systems. Much is expected of the ex-post legal regime of Competition law. The Competition Act, 2002, also, prohibits both vertical and horizontal practices in relation to cartelisation and collusion.

The presentation will basically deal with situations that normally arise in the health care delivery system in India and how ex-ante regulatory framework and Competition law could to a certain extent take care of situations so as to minimise the adverse impact of lack of competition in pharmaceutical drug markets on consumers in India.

Keywords: Competition law, healthcare, collusive practice, competition law India

Suggested Citation

Pai, Yogesh, Legal and Regulatory Instruments to Address Collusive Practices in Healthcare Delivery (July 6, 2010). Available at SSRN: https://ssrn.com/abstract=1638605 or http://dx.doi.org/10.2139/ssrn.1638605

Yogesh Pai (Contact Author)

National Law University Delhi, Centre for Innovation, IP and Competition (CIIPC) ( email )

Sector- 14, Dwarka
Dwarka
New Delhi, Delhi 110078
India
8826724506 (Phone)
8826724506 (Fax)

HOME PAGE: http://ciipc.org/

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
121
Abstract Views
765
Rank
344,045
PlumX Metrics